1-8 of 8
Jianchang Lin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 140.
https://doi.org/10.1182/blood-2019-128007
Published: 2019
Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1867.
https://doi.org/10.1182/blood-2019-125629
Published: 2019
Journal Articles

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Ajeeta B Dash, PhD, Jacob Zhang, PhD, Lei Shen, PhD, Bin Li, PhD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Hervé Avet-Loiseau, MDPhD, Nizar Bahlis, MD, Philippe Moreau, Paul Richardson, Alessandra Di Bacco, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 473.
https://doi.org/10.1182/blood-2018-99-114614
Published: 2018
Journal Articles

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Clinical Trials & Observations
Hervé Avet-Loiseau, Nizar J. Bahlis, Wee-Joo Chng, Tamas Masszi, Luisa Viterbo, Ludek Pour, Peter Ganly, Antonio Palumbo, Michele Cavo, Christian Langer, Andrzej Pluta, Arnon Nagler, Shaji Kumar, Dina Ben-Yehuda, S. Vincent Rajkumar, Jesus San-Miguel, Deborah Berg, Jianchang Lin, Helgi van de Velde, Dixie-Lee Esseltine, Alessandra di Bacco, Philippe Moreau, Paul G. Richardson
Journal: Blood
Blood (2017) 130 (24): 2610–2618.
https://doi.org/10.1182/blood-2017-06-791228
Published: 2017
Includes: Supplemental data
Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Alessandra Di Bacco, PhD, Nizar J. Bahlis, MD, Nikhil C Munshi, MD, Hervé Avet-Loiseau, MD PhD, Tamás Masszi, MD, Luísa Viterbo, MD, Ludek Pour, MD PhD, Peter Ganly, BMBCh, PhD, Michele Cavo, MD, Christian Langer, MD, Shaji Kumar, MD, S. Vincent Rajkumar, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Ling Wang, PhD, Dixie-Lee Esseltine, MD, Katarina Luptakova, Helgi van de Velde, MD PhD, Paul G. Richardson, MD, Philippe Moreau
Journal: Blood
Blood (2016) 128 (22): 243.
https://doi.org/10.1182/blood.V128.22.243.243
Published: 2016
Journal Articles

Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)

Laurent Garderet, MD PhD, Jacob P. Laubach, MD, Anne-Marie Stoppa, MD, Parameswaran Hari, MD MRCP, MS, Michele Cavo, MD, Heinz Ludwig, MD, Maria-Victoria Mateos, MD PhD, Katarina Luptakova, Jianchang Lin, PhD, Helgi van de Velde, MD PhD, Deborah Berg, RN, MSN, Philippe Moreau, Paul G. Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 2134.
https://doi.org/10.1182/blood.V128.22.2134.2134
Published: 2016
Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, MD, Norbert Grzasko, MD PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 727.
https://doi.org/10.1182/blood.V126.23.727.727
Published: 2015
Journal Articles

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Shaji K. Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Mehdi Hamadani, MD, A. Keith Stewart, MBA, MB, CHB, Vivek Roy, M.D., Parameswaran Hari, MBBS, MD, MRCP, Robert Vescio, MD, Deborah Berg, RN, MSN, Jianchang Lin, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2012) 120 (21): 332.
https://doi.org/10.1182/blood.V120.21.332.332
Published: 2012